Asthma Drug Could Help Overcome Cancer Immunotherapy Resistance

Immunotherapy has fundamentally reshaped cancer treatment in recent years, yet certain aggressive forms, such as triple-negative breast cancer, frequently remain resistant to these therapies. A significant study published in Nature Cancer suggests a potential breakthrough by repurposing a medication already in use for decades to treat asthma.

Researchers at Northwestern University have identified a protein called CysLTR1 as a critical biological pathway that tumors exploit to evade the immune system. This protein, which plays a known role in asthma and allergic reactions, is the primary target of montelukast, a medication commonly prescribed to asthma patients.

Reprogramming the Immune Response

The study reveals that cancer cells are capable of hijacking white blood cells known as neutrophils. While these cells are typically tasked with fighting infections and tumors, the presence of the tumor causes them to shift roles, ultimately promoting cancer growth instead of suppressing it.

In various preclinical models—including breast, colon, ovarian, and prostate cancers, as well as melanoma—blocking CysLTR1 was found to slow tumor growth and improve survival rates. Notably, the researchers observed that tumors previously resistant to immunotherapy began to respond to treatment once this biological “switch” was deactivated.

Did You Know? The drug montelukast, currently being studied for its potential to combat cancer, is a well-established medication that has been used for decades to manage asthma and allergic reactions.

The Path Toward Clinical Application

Because montelukast is already a widely used and well-understood medication, researchers suggest that the path toward human clinical trials could potentially be accelerated. By “reprogramming” neutrophils to act as allies rather than enemies, this approach could offer a new strategy for treating cancers that are currently difficult to manage.

Northwestern University study recommends expanding lung cancer screening ages

However, the research team remains cautious. While these results are promising, they have been observed exclusively in preclinical models. Before this method can be integrated into standard oncology practice, the findings must be rigorously confirmed in human patients.

Expert Insight: The potential to re-sensitize resistant tumors to immunotherapy by targeting the CysLTR1 pathway represents a significant shift in perspective. By focusing on the tumor’s manipulation of the immune microenvironment, we may be able to restore the body’s natural ability to fight malignancy, provided that future human trials validate these early findings.

Frequently Asked Questions

What is the role of the protein CysLTR1 in cancer?
CysLTR1 is a protein that certain tumors use as a pathway to evade the immune system. By exploiting this mechanism, tumors can turn white blood cells called neutrophils into allies that support cancer growth rather than fighting it.

How does montelukast influence tumor growth?
Montelukast is a drug that targets and blocks the CysLTR1 protein. In preclinical studies, blocking this protein slowed tumor growth and helped the immune system regain its ability to fight the cancer.

Can this treatment be used for patients immediately?
No. While the drug is already used for asthma, these specific results were obtained in preclinical models. The findings must be confirmed through clinical trials in humans before the treatment can be used in oncology.

How might the repurposing of existing, well-known medications change your perspective on the future of cancer research?